UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM | |||||
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): February 23, 2022
 | ||
| (Exact name of registrant as specified in its charter) | ||
(State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||
(Address of principal executive offices) (Zip Code)
(650 ) 837-7000
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01 Other Events
On February 23, 2022, Exelixis, Inc. (Exelixis) filed a complaint in the United States District Court for the District of Delaware for patent infringement against MSN Pharmaceuticals, Inc. (MSN) asserting infringement of U.S. Patent Nos. 11,091,439, 11,091,440 and 11,098,015 (the 2022 MSN ANDA Complaint) arising from MSN’s further amendment of its Abbreviated New Drug Application (ANDA), originally filed with the U.S. Food and Drug Administration (FDA) in September 2019 for a generic version of CABOMETYX® (cabozantinib) tablets (20 mg / 40 mg / 60 mg) and first amended by MSN in May 2020. As further amended, MSN’s ANDA now requests approval to market a generic version of CABOMETYX® tablets prior to expiration of U.S. Patent Nos. 11,091,439, 11,091,440 and 11,098,015. In the 2022 MSN ANDA Complaint, Exelixis is seeking, among other remedies, equitable relief enjoining MSN from infringing these patents, as well as an order that the effective date of any FDA approval of MSN’s ANDA would be a date no earlier than the expiration of the patents identified in the 2022 MSN ANDA Complaint, the latest of which expires on January 15, 2030. The 2022 MSN ANDA Complaint is a new case against MSN involving Exelixis patents that are different from those asserted in the consolidated Civil Action Nos. 19-2017 and 20-006 (collectively, the 2019/2020 MSN ANDA Actions) described below. A trial has not yet been scheduled in connection with the 2022 MSN ANDA Complaint.
The 2019/2020 MSN ANDA Actions arise from complaints filed by Exelixis against MSN in 2019 and 2020. On October 29, 2019, Exelixis filed a complaint against MSN asserting infringement of U.S. Patent No. 8,877,776. On May 11, 2020, Exelixis filed an additional complaint against MSN asserting infringement of U.S. Patent Nos. 7,579,473 and 8,497,284. The 2019/2020 MSN ANDA Actions are scheduled for a single, consolidated trial in May 2022. Exelixis is seeking, among other remedies, equitable relief enjoining MSN from infringing U.S. Patent Nos. 8,877,776, 7,579,473 and 8,497,284, as well as an order that the effective date of any FDA approval of MSN’s ANDA would be a date no earlier than the expiration of the patents at issue in the 2019/2020 MSN ANDA Actions, the latest of which expires on October 8, 2030.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
EXELIXIS, INC. | |||||||||||
| February 23, 2022 | /s/ JEFFREY J. HESSEKIEL | ||||||||||
| Date | Jeffrey J. Hessekiel | ||||||||||
| Executive Vice President and General Counsel | |||||||||||